Payment overview · 2025
General Payments
$254.52
13 reported records · 9 companies
Healthcare provider profile · identity verified
Matthew Block, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · LAURINBURG, NC · NPI 1417997172
Verified facts
What the public records show
CMS Open Payments records show Matthew Block, MD received $254.52 in general payments during 2025 across 13 reported records.
Esperion Therapeutics, Inc. accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 439 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 628 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 439 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $65.70 | 25.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.94 | 15.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.45 | 13.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.63 | 9.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.68 | 8.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.13 | 8.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $19.27 | 7.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.74 | 5.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.98 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.52 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $65.70 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.94 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 439 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
439 | 93 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
183 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
628 | 122 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
101 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
439 | 93 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 628 | 122 |
| Furosemide | Furosemide | 565 | 158 |
| Gabapentin | Gabapentin | 501 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 454 | 124 |
| Eliquis | Apixaban | 439 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 95 |
| Spironolactone | Spironolactone | 318 | 103 |
| Atenolol | Atenolol | 313 | 86 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 285 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 264 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 260 | 81 |
| Bumetanide | Bumetanide | 232 | 60 |
| Carvedilol | Carvedilol | 232 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 79 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 212 | 60 |
| Amiodarone Hcl | Amiodarone Hcl | 205 | 43 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 198 | 50 |
| Losartan Potassium | Losartan Potassium | 189 | 62 |
| Quetiapine Fumarate | Quetiapine Fumarate | 187 | 43 |
| Mounjaro | Tirzepatide | 183 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 48 |
| Omeprazole | Omeprazole | 158 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 151 | 51 |
| Nitroglycerin | Nitroglycerin | 148 | 75 |
| Potassium Chloride | Potassium Chloride | 143 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 136 | 34 |
| Prednisone | Prednisone | 136 | 47 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 130 | 54 |
| Lisinopril | Lisinopril | 106 | 34 |
| Entresto | Sacubitril/Valsartan | 104 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 28 |
| Rybelsus | Semaglutide | 101 | 27 |
| Allopurinol | Allopurinol | 90 | 30 |
| Celecoxib | Celecoxib | 86 | 30 |
| Digoxin | Digoxin | 84 | 26 |
| Ezetimibe | Ezetimibe | 75 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 32 |
| Clonidine Hcl | Clonidine Hcl | 65 | 20 |
| Warfarin Sodium | Warfarin Sodium | 65 | 18 |
| Ibuprofen | Ibuprofen | 64 | 18 |
| Linzess | Linaclotide | 62 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 61 | 19 |
| Trazodone Hcl | Trazodone Hcl | 60 | 17 |
| Famotidine | Famotidine | 57 | 17 |
| Promethazine Hcl | Promethazine Hcl | 57 | 16 |
| Xarelto | Rivaroxaban | 56 | 12 |
| Flecainide Acetate | Flecainide Acetate | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 14 |
| Sertraline Hcl | Sertraline Hcl | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 49 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Metformin Hcl | Metformin Hcl | 45 | 14 |
| Simvastatin | Simvastatin | 45 | 13 |
| Sucralfate | Sucralfate | 44 | 11 |
| Ranolazine Er | Ranolazine | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 12 |
| Methylprednisolone | Methylprednisolone | 37 | 27 |
| Finasteride | Finasteride | 34 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 11 |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 18 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Nifedipine Er | Nifedipine | 24 | 11 |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 13 |
| Penicillin V Potassium | Penicillin V Potassium | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.52 · 13 records | Esperion Therapeutics, Inc. | CAMZYOS, ELIQUIS, JARDIANCE, LifeVest, NEXLETOL, VERQUVO, WATCHMAN FLX, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error